Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 270

1.

Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer.

Gong X, Siprashvili Z, Eminaga O, Shen Z, Sato Y, Kume H, Homma Y, Ogawa S, Khavari PA, Pollack JR, Brooks JD.

Oncotarget. 2017 Mar 21;8(12):18657-18669. doi: 10.18632/oncotarget.15703.

2.

Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.

Kirby MK, Ramaker RC, Roberts BS, Lasseigne BN, Gunther DS, Burwell TC, Davis NS, Gulzar ZG, Absher DM, Cooper SJ, Brooks JD, Myers RM.

BMC Cancer. 2017 Apr 17;17(1):273. doi: 10.1186/s12885-017-3252-2.

3.

NUSAP1 promotes invasion and metastasis of prostate cancer.

Gordon CA, Gong X, Ganesh D, Brooks JD.

Oncotarget. 2017 Feb 22. doi: 10.18632/oncotarget.15604. [Epub ahead of print]

4.

Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids.

Banerjee S, Zare RN, Tibshirani RJ, Kunder CA, Nolley R, Fan R, Brooks JD, Sonn GA.

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3334-3339. doi: 10.1073/pnas.1700677114. Epub 2017 Mar 14.

PMID:
28292895
5.

Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.

Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y; Canary Prostate Active Surveillance Study Investigators..

Eur Urol. 2016 Nov 23. pii: S0302-2838(16)30850-8. doi: 10.1016/j.eururo.2016.11.017. [Epub ahead of print]

PMID:
27889277
6.

MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.

Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD.

PLoS One. 2016 Nov 15;11(11):e0165236. doi: 10.1371/journal.pone.0165236. eCollection 2016.

7.

Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.

Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM Jr, Wagner AA, Wei JT, Lin DW.

J Urol. 2017 Apr;197(4):1026-1033. doi: 10.1016/j.juro.2016.10.090. Epub 2016 Nov 1.

PMID:
27810448
8.

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.

McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Am J Surg Pathol. 2016 Nov;40(11):1439-1456.

PMID:
27635949
9.

Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.

Brooks JD, John EM, Mellemkjaer L, Lynch CF, Knight JA, Malone KE, Reiner AS, Bernstein L, Liang X, Shore RE, Stovall M; WECARE Study Collaborative Group., Bernstein JL.

Cancer Med. 2016 Nov;5(11):3282-3291. doi: 10.1002/cam4.890. Epub 2016 Oct 3.

10.

Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?

Leppert JT, Mittakanti HR, Thomas IC, Lamberts RW, Sonn GA, Chung BI, Skinner EC, Wagner TH, Chertow GM, Brooks JD.

Urology. 2017 Feb;100:65-71. doi: 10.1016/j.urology.2016.08.044. Epub 2016 Sep 12.

PMID:
27634733
11.

PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Eur Urol Focus. 2016 Jun;2(2):180-188.

PMID:
27617307
12.

Pharmacokinetics of 14 C-ortho-phenylphenol following intravenous administration in pigs.

Nixon E, Brooks JD, Routh PA, Chittenden JT, Baynes RE.

J Appl Toxicol. 2017 Apr;37(4):508-512. doi: 10.1002/jat.3380. Epub 2016 Sep 4.

PMID:
27593710
13.

Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries.

Mittakanti HR, Thomas IC, Shelton JB, Makarov DV, Skolarus TA, Cooperberg MR, Chung BI, Sonn GA, Brooks JD, Leppert JT.

J Clin Oncol. 2016 Jul 25. pii: JCO689216. [Epub ahead of print] No abstract available.

PMID:
27458297
14.

A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.

Liss MA, Schenk JM, Faino AV, Newcomb LF, Boyer H, Brooks JD, Carroll PR, Dash A, Fabrizio MD, Gleave ME, Nelson PS, Neuhouser ML, Wei JT, Zheng Y, Wright JL, Lin DW, Thompson IM.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):390-394. doi: 10.1038/pcan.2016.28. Epub 2016 Jul 19.

PMID:
27431498
15.

Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.

Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L.

Prostate. 2016 Nov;76(15):1409-19. doi: 10.1002/pros.23225. Epub 2016 Jun 21.

PMID:
27325561
16.

Reply to being a widower may be an indication for routine prostate-specific antigen screening above age 69 years, which the American Urological Association recommends as a cutoff point.

Gomez SL, Martínez ME, Brooks JD, Cheng I, Lichtensztajn D, Murphy JD.

Cancer. 2016 Aug 15;122(16):2604-6. doi: 10.1002/cncr.30097. Epub 2016 Jun 10. No abstract available.

PMID:
27286520
17.

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.

Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA.

Mod Pathol. 2016 Aug;29(8):904-14. doi: 10.1038/modpathol.2016.88. Epub 2016 May 13.

18.

Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3.

PMID:
27136741
19.

Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?

Barbosa PV, Thomas IC, Srinivas S, Buyyounouski MK, Chung BI, Chertow GM, Asch SM, Wagner TH, Brooks JD, Leppert JT.

Eur Urol. 2016 Aug;70(2):227-30. doi: 10.1016/j.eururo.2016.02.037. Epub 2016 Mar 2.

PMID:
26948397
20.

Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study.

Sisti JS, Bernstein JL, Lynch CF, Reiner AS, Mellemkjaer L, Brooks JD, Knight JA, Bernstein L, Malone KE, Woods M, Liang X, John EM; WECARE Study Collaborative Group..

Springerplus. 2015 Dec 30;4:825. doi: 10.1186/s40064-015-1642-y. eCollection 2015.

Supplemental Content

Loading ...
Support Center